Using human cancer cells, tumour and blood samples from cancer patients, researchers at Johns Hopkins Medicine have uncovered the role of a neurotransmitter in the spread of aggressive cancers.
Neurotransmitters are chemical "messengers" that transmit impulses from neurons to other target cells.
The work, described in the journal Cell Reports, found that this neurotransmitter, called N-acetyl-aspartyl-glutamate (NAAG) NAAG is more abundant in cancers with a tendency to grow and spread rapidly - or so-called higher grade cancers - than in lower grade tumours, making it a potential marker for tumour progression or regression during cancer therapy, the researchers say.
The experiments also demonstrated that NAAG is a source of glutamate, a chemical that cancer cells use as building blocks to survive, in tumours that express an enzyme called glutamate carboxypeptidase II (GCPII).
The group also discovered that stopping the GCPII from being active by using a drug called 2-PMPA to treat human ovarian tumours implanted in ovaries of mice, reduced tumour weights and glutamate concentrations.
They noted that targeting both GCPII and glutaminase, the enzyme that converts glutamine to glutamate, resulted in a more substantial tumour reduction in patient-derived pancreatic cancer tumours implanted in pancreas of mice, since it attacked the production of glutamate from both glutamine and from NAAG.
"Our study suggest that NAAG serves as an important reservoir to provide glutamate to cancer cells through GCPII, when glutamate production from other sources is limited," says senior study author Anne Le, M.D., H.D.R, an associate professor of pathology and oncology at Johns Hopkins. GCPII inhibitor is found to be well-tolerated in clinical trials for pain, so we should be able to move it into clinical trials for cancer therapy quickly."
Le and colleagues in her Cancer Metabolism Laboratory conducted several laboratory experiments to study NAAG.
They first used a technique called mass spectroscopy to measure break down products produced from amino acid glutamine, finding that NAAG production is more abundant in advanced human Burkitt lymphoma cells transformed by the cancer gene MYC than in those not transformed by MYC.
They also found NAAG more abundant in human high-grade ovarian cancer cells than in human primary ovarian tumours, and in consistently higher concentrations in patient samples of glioblastoma brain tumours compared to slower-growing meningioma brain tumours.
Le's team then looked to see whether overall levels of NAAG in human patients correlated with the grades of their tumours.
Measuring concentrations of NAAG in blood plasma samples from brain tumour patients, the investigators found significantly higher NAAG concentrations in samples from patients who had glioblastoma multiforme, the most aggressive brain cancer, than in patients who had gliomas or meningiomas.
Using human Burkitt's lymphoma tumour model in mice, the researchers also found NAAG levels rose and fell in response to tumour growth and regression.
"Together, these findings strongly link plasma concentrations of NAAG with tumour growth rates, and suggest that measurements of NAAG in peripheral blood should be further explored for timely monitoring of tumour growth during cancer treatment," Le says. "These results don't make NAAG a potential diagnostic marker, but a prognostic marker, a potentially valuable way for noninvasive assessments of tumour progression."
Previous studies directed by Le, and described in 2012 in the journal Cell Metabolism, and in 2016 in the journal Proceedings of the National Academy of Sciences found that glutamine metabolism plays an important role in cancer growth.
"Seven years ago, we found that glutamine was a big deal in cancer metabolism, and inhibiting the conversion of glutamine to glutamate was the right target to curb cancer growth," Le says. "It turns out, that's correct. But it's not enough, because cancer cells have another way to make glutamate through this hidden reservoir. Targeting both pathways could improve cancer treatments," she adds.
Le cautions that these findings are only applicable to cancers that express GCPII. "For GCPII-negative cancers, she says NAAG could be taking on another role to promote cancer cell growth through an alternative pathway, but studies would need to be done to confirm that idea".
Source: Johns Hopkins Medicine
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.